Compounds > n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid
Page last updated: 2024-09-05

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Peritoneal Diseases

n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid has been researched along with Peritoneal Diseases in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abdulla, A; Albert, PS; Brady, ED; Brechbiel, MW; Garmestani, K; Ma, D; Milenic, DE1

Other Studies

1 other study(ies) available for n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Peritoneal Diseases

ArticleYear
Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-01, Volume: 10, Issue:23

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Colonic Neoplasms; Female; Humans; Indium Radioisotopes; Isothiocyanates; Mice; Mice, Nude; Pentetic Acid; Peritoneal Diseases; Pilot Projects; Radioimmunotherapy; Receptor, ErbB-2; Stereoisomerism; Survival Rate; Tissue Distribution; Transplantation, Heterologous; Trastuzumab

2004